Related Experiment Video
Updated: Aug 6, 2026
09:33
Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis
Published on: March 20, 2026
A multistakeholder call for belzutifan biomarker data in advanced pheochromocytoma and paraganglioma
Rodrigo A Toledo1, Carlota Arenillas1, Patricia L M Dahia2
1Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
Trends in Endocrinology and Metabolism: TEM
|July 21, 2026
Abstract:
The HIF-2α inhibitor belzutifan was recently U.S. Food and Drug Administration (FDA)-approved for advanced pheochromocytoma/paraganglioma. This multistakeholder article calls for clinical-trial genomic correlates and outcome data to clarify efficacy across these molecularly heterogeneous neuroendocrine tumors.
